Systemic Triple Therapy in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Systemic Triple Therapy in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Blog Article

For many years, androgen deprivation therapy (ADT) as monotherapy has been the gold standard for metastatic hormone-sensitive prostate cancer (mHSPC) treatment.Several studies have been published within the last decade demonstrating a significant read more survival advantage resulting from combining the treatment with standard ADT plus docetaxel or androgen receptor targeted therapy (ARTA) compared to ADT monotherapy.Recently published data of the PEACE-1 acupatch and ARASENS trials suggest that in the future, triple therapy might be a treatment option for patients with mHSPC.